First presented in 2013, LER occurs when specific drug formulations—typically those containing a combination of a (like citrate or phosphate) and a surfactant
The report was developed by a task force including experts from the U.S. FDA and the pharmaceutical industry to address the following: pda technical report 82
In the world of biologics manufacturing, ensuring patient safety means more than just following a checklist—it means understanding the hidden behaviors of the products we create. One of the most significant challenges in recent years has been Low Endotoxin Recovery (LER) To help the industry tackle this head-on, the Parenteral Drug Association (PDA) Technical Report No. 82 (TR 82) First presented in 2013, LER occurs when specific
Since the publication of PDA TR 82, the conversation has evolved. The USP is currently working on a new general chapter (USP <1085> – "Low Endotoxin Recovery" ) which will likely adopt many principles from TR 82. 82 (TR 82) Since the publication of PDA
